respiratory syncytial virus vaccine
Trade name: ABRYSVO
VaccineapprovedBreakthrough Therapy FDA
Approved
May 31, 2023
Clinical trial activity
6 trials · 7 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
4
Phase 4
1
Earliest trial started Nov 13, 2024 (NCT06642558)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Approval history
- approvedBreakthroughMay 31, 2023
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07232706 | Phase 3 | Jan 31, 2026 | CH Annecy, University of Paris |
| NCT07296120 | Phase 4 | Jan 1, 2026 | Rowan University |
| NCT07272434 | Phase 3 | Oct 22, 2025 | Government of China, MAXVAX Biotechnology Limited Liability Company |
| NCT07041190 | Phase 3 | Sep 30, 2025 | PENTA Foundation |
| NCT06890416 | Phase 3 | Apr 4, 2025 | Pfizer |
| NCT06642558 | Phase 1/Phase 2 (Phase 2) | Nov 13, 2024 | Government of China, MAXVAX Biotechnology Limited Liability Company |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 0 | 2 | 2024 |
| MAXVAX Biotechnology Limited Liability Company | For profit | 2 | 2 | 2 | 2024 |
| CH Annecy | Academic/Hospital | 1 | 1 | 1 | 2026 |
| PENTA Foundation | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Pfizer | For profit | 1 | 1 | 1 | 2025 |
| Rowan University | Academic/Hospital | 1 | 0 | 1 | 2026 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2026 |
7 organizations
Page 1 / 1